GEN Exclusives

More »

GEN News Highlights

More »
Nov 10, 2006

Allergan Will Distribute Certain Ivivi Products

  • Allergan obtained the exclusive right to market, sell, and distribute some of Ivivi’s products in the aesthetic and bariatric medical procedure markets on a worldwide basis. Under the agreement, Ivivi will receive $1.5 million plus additional royalty-based fees.

    Ivivi is entitled to an initial payment and milestone payments upon initiation of commercial sales of the products in the U.S. and Europe. Of the $1.5 million, $500,000 is payable within five days of the agreement signing. Ivivi will also receive a specified price per unit and royalty payments.

    Ivivi will manufacture and supply Inamed, a wholly owned subsidiary of Allergan, with the products under an eight-year contract beginning with the first commercial sale. Inamed may extend the term for two years without further payment and may extend the term for up to eight years by paying an extension fee.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »